{"id":44284,"date":"2025-10-24T22:43:25","date_gmt":"2025-10-24T14:43:25","guid":{"rendered":"https:\/\/flcube.com\/?p=44284"},"modified":"2025-10-24T22:43:26","modified_gmt":"2025-10-24T14:43:26","slug":"cspcs-syh2061-injection-receives-nmpa-clinical%e2%80%91trial-approval-for-iga-nephropathy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44284","title":{"rendered":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy"},"content":{"rendered":"\n<p>CSPC Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that its independently developed Class\u202f1 chemical novel drug <strong>SYH2061 Injection<\/strong> (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>SYH2061 Injection \u2013 siRNA targeting complement protein C5<\/td><\/tr><tr><td><strong>Delivery<\/strong><\/td><td>Subcutaneous, GalNAc\u2011conjugated for liver\u2011specific uptake<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>IgA nephropathy &amp; other complement\u2011mediated diseases<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA clinical\u2011trial approval (Phase\u202f1) \u2013 first independent Chinese siRNA in trial<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Engineered siRNA with optimized sequence &amp; chemical modifications for sustained gene silencing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-syh2061-matters\"><strong>Why SYH2061 Matters<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011of\u2011its\u2011kind in China<\/strong>: The drug represents the first domestically\u2011developed siRNA to secure clinical\u2011trial approval, breaking a long\u2011standing dependence on imported RNA therapeutics.<\/li>\n\n\n\n<li><strong>Ultra\u2011long\u2011acting C5 knockdown<\/strong>: Leveraging GalNAc\u2011mediated hepatocyte targeting, SYH2061 achieves sustained suppression of C5 protein, potentially reducing the need for frequent dosing.<\/li>\n\n\n\n<li><strong>Complement\u2011mediated disease focus<\/strong>: By directly silencing a key driver of inflammation, SYH2061 offers a novel mechanism for conditions such as IgA nephropathy, atypical hemolytic\u2011uremic syndrome, and paroxysmal nocturnal hemoglobinuria.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-pathway\"><strong>Regulatory Pathway<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA Clinical\u2011Trial Approval<\/strong>: The drug entered the \u201cClass\u202f1 chemical novel drug\u201d pathway, a highly selective category reserved for advanced therapeutics.<\/li>\n\n\n\n<li><strong>Expedited Review<\/strong>: CSPC benefited from the NMPA\u2019s priority review framework, underscoring the unmet medical need in complement disorders.<\/li>\n\n\n\n<li><strong>Next Steps<\/strong>: CSPC will launch a Phase\u202f1\/2 dose\u2011escalation study in early 2026, with plans to collaborate with academic centers for biomarker development.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-outlook\"><strong>Commercial Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Potential<\/strong>: IgA nephropathy affects >\u202f150\u202fmillion individuals worldwide; China alone accounts for ~\u202f10\u202f% of the global patient population.<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: CSPC is negotiating with Chinese payers to secure a reimbursement pathway that reflects the drug\u2019s disease\u2011modifying potential.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Successful clinical outcomes could pave the way for regulatory submissions in the U.S. (FDA) and EU (EMA), leveraging CSPC\u2019s existing commercialization platform.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102400802_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102400802_c.\"><\/object><a id=\"wp-block-file--media-3f976f02-a2ca-41e3-99de-3bd32574479b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102400802_c.pdf\">2025102400802_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102400802_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3f976f02-a2ca-41e3-99de-3bd32574479b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44286,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855,64],"class_list":["post-44284","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44284\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44284\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T14:43:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-24T14:43:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy\",\"datePublished\":\"2025-10-24T14:43:25+00:00\",\"dateModified\":\"2025-10-24T14:43:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284\"},\"wordCount\":374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2401.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44284#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44284\",\"name\":\"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2401.webp\",\"datePublished\":\"2025-10-24T14:43:25+00:00\",\"dateModified\":\"2025-10-24T14:43:26+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44284\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2401.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44284#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44284","og_locale":"en_US","og_type":"article","og_title":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.","og_url":"https:\/\/flcube.com\/?p=44284","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T14:43:25+00:00","article_modified_time":"2025-10-24T14:43:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44284#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44284"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy","datePublished":"2025-10-24T14:43:25+00:00","dateModified":"2025-10-24T14:43:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44284"},"wordCount":374,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44284#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44284#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44284","url":"https:\/\/flcube.com\/?p=44284","name":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44284#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44284#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","datePublished":"2025-10-24T14:43:25+00:00","dateModified":"2025-10-24T14:43:26+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class\u202f1 chemical novel drug SYH2061 Injection (a GalNAc\u2011conjugated double\u2011stranded small interfering RNA) has been granted clinical\u2011trial approval by the National Medical Products Administration (NMPA). The program targets IgA nephropathy and other complement\u2011mediated disorders, marking the first Chinese siRNA candidate to enter the clinical\u2011trial stage with an ultra\u2011long\u2011acting C5\u2011silencing profile.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44284#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44284"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44284#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","width":1080,"height":608,"caption":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44284#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC\u2019s SYH2061 Injection Receives NMPA Clinical\u2011Trial Approval for IgA Nephropathy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44284"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44284\/revisions"}],"predecessor-version":[{"id":44287,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44284\/revisions\/44287"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44286"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}